LncRNA diabetes regulated anti-inflammatory RNA (DRAIR) has been reported to be involved in diabetes-induced injury. However, its role in other human diseases is unclear. Our preliminary sequencing analysis showed its expression was altered in gastric cancer (GC). Thus, this study aimed to explore its diagnostic and prognostic values in GC. DRAIR expression in paired tumor and non-tumor tissues and plasma of GC patients and control samples was determined by RT-qPCR. The diagnostic value of DRAIR for early-stage GC was analyzed using ROC curve analysis. The prognostic value of DRAIR was explored by performing a follow-up (5-year) study. DRAIR expression was downregulated in GC tissues than in non-tumor tissues and in plasma of GC patients than in plasma of healthy controls. DRAIR expression in tumor tissues was closely and positively correlated with its expression in plasma. Plasma DRAIR effectively separated GC patients from controls. High DRAIR levels in tumor tissues and plasma samples were closely correlated with poor survival of GC patients. DRAIR is overexpressed in GC and may serve as an early diagnostic and prognostic biomarker for GC.

据报道，LncRNA 糖尿病调节的抗炎 RNA (DRAIR) 与糖尿病引起的损伤有关。然而，它在其他人类疾病中的作用尚不清楚。我们的初步测序分析显示其在胃癌 (GC) 中的表达发生了改变。因此，本研究旨在探讨其在 GC 中的诊断和预后价值。通过 RT-qPCR 确定 GC 患者和对照样品的配对肿瘤和非肿瘤组织和血浆中的 DRAIR 表达。采用ROC曲线分析DRAIR对早期GC的诊断价值。通过进行一项随访（5 年）研究探索了 DRAIR 的预后价值。DRAIR 在 GC 组织中的表达低于非肿瘤组织，在 GC 患者的血浆中低于健康对照的血浆。DRAIR在肿瘤组织中的表达与其在血浆中的表达密切且正相关。血浆 DRAIR 有效地将 GC 患者与对照组分开。肿瘤组织和血浆样本中的高 DRAIR 水平与 GC 患者的低生存率密切相关。DRAIR 在 GC 中过表达，可作为 GC 的早期诊断和预后生物标志物。